Ignite Creation Date:
2024-05-06 @ 9:52 AM
Last Modification Date:
2024-10-26 @ 12:21 PM
Study NCT ID:
NCT03097861
Status:
COMPLETED
Last Update Posted:
2020-01-14
First Post:
2017-03-27
Brief Title:
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone as Compared to Placebo
Sponsor:
Sucampo Pharma Americas LLC
Organization:
Mallinckrodt
Study Overview
Official Title:
A Randomized Placebo-controlled Double-blinded Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone as Compared to Placebo in Adult Subjects With Chronic Idiopathic Constipation
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone as compared to placebo when administered orally in participants with Chronic Idiopathic Constipation CIC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None